Characterization of Four New Monoclonal Antibodies Against the Distal N-terminal Region of PrP(c)

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2015 Mar 25

PMID 25802800

Citations 5

Authors

Alessandro Didonna

Anja Colja Venturini

Katrina Hartman

Tanja Vranac

Vladka curin Serbec

Giuseppe Legname

Affiliations

Soon will be listed here.

Abstract

Prion diseases are a group of fatal neurodegenerative disorders that affect humans and animals. They are characterized by the accumulation in the central nervous system of a pathological form of the host-encoded prion protein (PrP(C)). The prion protein is a membrane glycoprotein that consists of two domains: a globular, structured C-terminus and an unstructured N-terminus. The N-terminal part of the protein is involved in different functions in both health and disease. In the present work we discuss the production and biochemical characterization of a panel of four monoclonal antibodies (mAbs) against the distal N-terminus of PrP(C) using a well-established methodology based on the immunization of Prnp (0/0) mice. Additionally, we show their ability to block prion (PrP(Sc)) replication at nanomolar concentrations in a cell culture model of prion infection. These mAbs represent a promising tool for prion diagnostics and for studying the physiological role of the N-terminal domain of PrP(C).

Citing Articles

Prion Protein Endoproteolysis: Cleavage Sites, Mechanisms and Connections to Prion Disease.

Castle A, Westaway D J Neurochem. 2025; 169(1):e16310.

PMID: 39874431 PMC: 11774512. DOI: 10.1111/jnc.16310.

Beta-endoproteolysis of the cellular prion protein by dipeptidyl peptidase-4 and fibroblast activation protein.

Castle A, Kang S, Eskandari-Sedighi G, Wohlgemuth S, Nguyen M, Drucker D Proc Natl Acad Sci U S A. 2022; 120(1):e2209815120.

PMID: 36574660 PMC: 9910601. DOI: 10.1073/pnas.2209815120.

The E3 Ubiquitin Ligase TRAF6 Interacts with the Cellular Prion Protein and Modulates Its Solubility and Recruitment to Cytoplasmic p62/SQSTM1-Positive Aggresome-Like Structures.

Masperone L, Codrich M, Persichetti F, Gustincich S, Zucchelli S, Legname G Mol Neurobiol. 2022; 59(3):1577-1588.

PMID: 35000151 DOI: 10.1007/s12035-021-02666-6.

The Cellular Prion Protein Increases the Uptake and Toxicity of TDP-43 Fibrils.

Scialo C, Celauro L, Zattoni M, Tran T, Bistaffa E, Moda F Viruses. 2021; 13(8).

PMID: 34452489 PMC: 8402629. DOI: 10.3390/v13081625.

The role of prion strain diversity in the development of successful therapeutic treatments.

Holec S, Block A, Bartz J Prog Mol Biol Transl Sci. 2020; 175:77-119.

PMID: 32958242 PMC: 8939712. DOI: 10.1016/bs.pmbts.2020.07.001.

References

Turnbaugh J, Unterberger U, Saa P, Massignan T, Fluharty B, Bowman F . The N-terminal, polybasic region of PrP(C) dictates the efficiency of prion propagation by binding to PrP(Sc). J Neurosci. 2012; 32(26):8817-30. PMC: 3433751. DOI: 10.1523/JNEUROSCI.1103-12.2012. View

Trevitt C, Hosszu L, Batchelor M, Panico S, Terry C, Nicoll A . N-terminal domain of prion protein directs its oligomeric association. J Biol Chem. 2014; 289(37):25497-508. PMC: 4162156. DOI: 10.1074/jbc.M114.566588. View

Vital C, Gray F, Vital A, Ferrer X, Julien J . Prion disease with octapeptide repeat insertion. Clin Exp Pathol. 1999; 47(3-4):153-9. View

Kovacs G, Head M, Hegyi I, Bunn T, Flicker H, Hainfellner J . Immunohistochemistry for the prion protein: comparison of different monoclonal antibodies in human prion disease subtypes. Brain Pathol. 2002; 12(1):1-11. PMC: 8095765. DOI: 10.1111/j.1750-3639.2002.tb00417.x. View

White A, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S . Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature. 2003; 422(6927):80-3. DOI: 10.1038/nature01457. View

Nakamura S, Ono F, Hamano M, Odagiri K, Kubo M, Komatsuzaki K . Immunohistochemical detection of apolipoprotein E within prion-associated lesions in squirrel monkey brains. Acta Neuropathol. 2000; 100(4):365-70. DOI: 10.1007/s004010000200. View

Moore R, Herzog C, Errett J, Kocisko D, Arnold K, Hayes S . Octapeptide repeat insertions increase the rate of protease-resistant prion protein formation. Protein Sci. 2006; 15(3):609-19. PMC: 2249780. DOI: 10.1110/ps.051822606. View

Cohen F, Prusiner S . Pathologic conformations of prion proteins. Annu Rev Biochem. 1998; 67:793-819. DOI: 10.1146/annurev.biochem.67.1.793. View

Zulianello L, Kaneko K, Scott M, Erpel S, Han D, Cohen F . Dominant-negative inhibition of prion formation diminished by deletion mutagenesis of the prion protein. J Virol. 2001; 74(9):4351-60. PMC: 111952. DOI: 10.1128/jvi.74.9.4351-4360.2000. View

10.

Campana V, Zentilin L, Mirabile I, Kranjc A, Casanova P, Giacca M . Development of antibody fragments for immunotherapy of prion diseases. Biochem J. 2008; 418(3):507-15. DOI: 10.1042/BJ20081541. View

11.

Raeber A, Brandner S, Klein M, Benninger Y, Musahl C, Frigg R . Transgenic and knockout mice in research on prion diseases. Brain Pathol. 1998; 8(4):715-33. PMC: 8098451. DOI: 10.1111/j.1750-3639.1998.tb00197.x. View

12.

Sim V, Caughey B . Recent advances in prion chemotherapeutics. Infect Disord Drug Targets. 2009; 9(1):81-91. PMC: 3347484. DOI: 10.2174/1871526510909010081. View

13.

Supattapone S, Muramoto T, Legname G, Mehlhorn I, Cohen F, DeArmond S . Identification of two prion protein regions that modify scrapie incubation time. J Virol. 2001; 75(3):1408-13. PMC: 114047. DOI: 10.1128/JVI.75.3.1408-1413.2001. View

14.

Zeng F, Watt N, Walmsley A, Hooper N . Tethering the N-terminus of the prion protein compromises the cellular response to oxidative stress. J Neurochem. 2003; 84(3):480-90. DOI: 10.1046/j.1471-4159.2003.01529.x. View

15.

Lenac Rovis T, Legname G . Prion protein-specific antibodies-development, modes of action and therapeutics application. Viruses. 2014; 6(10):3719-37. PMC: 4213558. DOI: 10.3390/v6103719. View

16.

Perrier V, Solassol J, Crozet C, Frobert Y, Mourton-Gilles C, Grassi J . Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation. J Neurochem. 2004; 89(2):454-63. PMC: 2063508. DOI: 10.1111/j.1471-4159.2004.02356.x. View

17.

Budka H, Aguzzi A, Brown P, BRUCHER J, Bugiani O, Gullotta F . Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol. 1995; 5(4):459-66. DOI: 10.1111/j.1750-3639.1995.tb00625.x. View

18.

Brown D, Qin K, Herms J, Madlung A, Manson J, Strome R . The cellular prion protein binds copper in vivo. Nature. 1997; 390(6661):684-7. DOI: 10.1038/37783. View

19.

Solforosi L, Bellon A, Schaller M, Cruite J, Abalos G, Williamson R . Toward molecular dissection of PrPC-PrPSc interactions. J Biol Chem. 2007; 282(10):7465-71. DOI: 10.1074/jbc.M610051200. View

20.

Lauren J, Gimbel D, Nygaard H, Gilbert J, Strittmatter S . Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009; 457(7233):1128-32. PMC: 2748841. DOI: 10.1038/nature07761. View